TG Therapeutics, Inc. · Biotechnology

TGTX TG Therapeutics, Inc. · Earnings

Reports 2026-11-09 Pre-market · MonReaction day 11-09upcoming

Get TGTX's results by email the night it reports

EPS and revenue vs. estimates, plus the first-day move. Free — unsubscribe in one click.

Before the print

Now· T-7 → T-1 freeze

Before the print · expectations4 days to the print

Street consensus

$0.37EPS

$250MRevenue

No past prints on file yet.

Pricing going in · as of the 11-05 close

+8.7%Move over the last 20 sessionsLast 5 sessions −0.2%

−1.3 ptsvs sector (XLV)XLV over the same window +10.0%

61.0×Forward P/EOn consensus current-FY EPS of $0.95 · 11-05

What the record doesn't tell you

Which way does TGTX go on 11‑09?

Model lean for 11-09, and the evidence behind it
Move band, P10 – P90
Last 8 prints, quarter by quarter
Peers that already reported, and how they traded

Start 30-day free trialFull access · no card requiredHave an account? Sign inThe lean freezes the night before the print.

Report card

Next· 8-K + call· 11-09 Pre-market

The print · 8-K and callupcoming · 2026-11-09 · Pre-market

Revenue—

est. $250M

EPS—

est. $0.37

Guidance—read from the 8-K once filed

Reaction

Next· open / day / 5-day· 11-09 → day 5

open / day / 5-day · 11-09 → day 5

Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →

TG Therapeutics earnings preview: what the record says

TG Therapeutics (TGTX) is scheduled to report earnings on Nov 9, 2026, before the open. The consensus estimate calls for EPS of $0.37 on revenue of $250M.

NextPick tracks TGTX in its Biotech basket alongside VRTX, REGN, MRNA, BIIB, UTHR, INCY, BNTX and ALNY, whose prints read through to this one.

Figures come from NextPick's earnings-reaction ledger and the options market. Not investment advice.

TGTX earnings: key questions

When is TGTX's next earnings date?

TG Therapeutics is scheduled to report on Nov 9, 2026, before the open.

What are TGTX's earnings expectations?

Analysts expect EPS of $0.37 on revenue of $250M for the quarter.